睿知中国医院研究地图
候选清单

正在招募乳腺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer

ClinicalTrials.gov 上登记的一项乳腺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06471205,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Subjects with histologically and/or cytologically confirmed, inoperable locally advanced or recurrent or metastatic triple-negative breast cancer;

    入选标准第 5 条

  3. Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by NCI-CTCAE v5.0;

    入选标准第 10 条

    6 months prior to screening needs treatment intervention unstable thrombotic events;

    排除标准第 13 条

  4. ECOG 0 or 1;

    入选标准第 4 条

  5. No blood transfusion, no use of cell growth factors and/or platelet raising drugs within 14 days before screening, and the organ function level must meet the requirements;

    入选标准第 9 条

  6. Must have at least one place in accordance with RECIST v1.1 define measurable lesions;

    入选标准第 8 条

  7. Other malignant tumors that progressed or required treatment within 5 years before the first dose;

    排除标准第 9 条

    HIV antibody positive, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;

    排除标准第 18 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06471205,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Voluntarily sign the informed consent and follow the requirements of the protocol;
  2. Age: ≥18 years old and ≤75 years old;
  3. Expected survival time ≥3 months;
  4. ECOG 0 or 1;
  5. Subjects with histologically and/or cytologically confirmed, inoperable locally advanced or recurrent or metastatic triple-negative breast cancer;
  6. Patients should not have received previous systemic therapy for unresectable, locally advanced, recurrent, or metastatic triple-negative breast cancer;
  7. A archived tumor tissue specimen or fresh tissue specimen of the primary or metastatic lesion within 2 years must be provided;
  8. Must have at least one place in accordance with RECIST v1.1 define measurable lesions;
  9. No blood transfusion, no use of cell growth factors and/or platelet raising drugs within 14 days before screening, and the organ function level must meet the requirements;
  10. Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by NCI-CTCAE v5.0;
  11. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, the serum or urine pregnancy test must be negative, and the patient must not be lactating; All enrolled patients should take adequate barrier contraception during the entire treatment cycle and for 6 months after the end of treatment.

排除标准:Exclusion Criteria:

  1. ADC drugs that have received topoisomerase I inhibitors as small molecule toxins;
  2. Palliative radiotherapy within 2 weeks before the first dose;
  3. Patients with checkpoint inhibitors prior to neoadjuvant/adjuvant chemotherapy;
  4. Use of an immunomodulatory drug within 14 days before the first dose of study drug;
  5. The history of severe cardiovascular and cerebrovascular diseases in the past six months was screened;
  6. QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;
  7. Active autoimmune and inflammatory diseases;
  8. Receiving long-term systemic corticosteroid therapy, etc., before the first dose;
  9. Other malignant tumors that progressed or required treatment within 5 years before the first dose;
  10. Presence of: a) poorly controlled diabetes mellitus before starting study treatment; b) severe complications associated with diabetes mellitus; c) a glycated hemoglobin level of 8% or more; d) hypertension poorly controlled by two antihypertensive drugs; e) history of hypertensive crisis or hypertensive encephalopathy;
  11. Present grade ≥2 radiation pneumonitis according to the RTOG/EORTC definition; Patients with current ILD;
  12. Complicated with pulmonary diseases leading to clinically severe respiratory impairment;
  13. 6 months prior to screening needs treatment intervention unstable thrombotic events;
  14. Patients with active central nervous system metastases;
  15. Patients with massive or symptomatic effusions or poorly controlled effusions;
  16. Allergic history to recombinant humanized antibody or human-mouse chimeric antibody or allergic to any excipients of the test drug;
  17. Prior organ transplantation or allogeneic hematopoietic stem cell transplantation;
  18. HIV antibody positive, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;
  19. Serious infection within 4 weeks before the first dose of study drug; Signs of pulmonary infection or active pulmonary inflammation within 4 weeks;
  20. Participated in another clinical trial within 4 weeks before the first dose;
  21. Patients with superior vena cava syndrome should not be rehydrated;
  22. Have a history of psychotropic substance abuse with an inability to quit or a history of severe neurological or psychiatric illness;
  23. Imaging examination showed that the tumor had invaded or wrapped the large thoracic vessels;
  24. Serious unhealed wound, ulcer, or fracture within 4 weeks before signing the informed consent;
  25. Clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;
  26. Subjects who are scheduled to receive live vaccine or receive live vaccine within 28 days before the first dose;
  27. Other circumstances considered by the investigator to be inappropriate for participation in the trial.

引自 ClinicalTrials.gov, NCT06471205, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06471205,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06471205